|Tel||+44 (0)1865 74171|
|Fax||+44 (0)1865 793101|
Dementia Clinical Network Lead - Oxford Academic Health Science Network
- Consultant Psychiatrist
I am interested in dementia and in treatment resistant depression and lead the Clinical Dementia Network of the Oxford Academic Health Science Network, which covers Berkshire, Buckinghamshire, Oxfordshire, Milton Keynes and Bedfordshire. I also lead the Thames Valley DeNDRoN local research network, which supports a wide variety of studies in dementia and neurological disease, has an excellent track record of recruitment and study delivery, and is focused on innovative strategies to integrate research and clinical practice. I am the Coordinating Editor of the Cochrane Dementia and Cognitive Improvement Group and lead an NIHR programme on reviews of diagnostic test accuracy in dementia. We are leading an international initiative to improve standards of reporting of diagnostic studies. I am interested in the problem of people with dementia who get lost and have created a new, volunteer-based service to mitigate its impact: Neighbourhood Return.
The possibility that ketamine infusions could be given in routine NHS ECT suites to patients with treatment resistant depression is the focus of an NIHR funded study which I lead. We are also collaborating with colleagues from Department of Primary Care Health Sciences to explore the range of experiences of people receiving ECT and to create a ‘Healthtalkonline’ module for ECT.
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
Knapp M. et al, (2016), Int J Geriatr Psychiatry
Ketamine: stimulating antidepressant treatment?
Malhi GS. et al, (2016), BJPsych Open, 2, e5 - e9
Dementia and Physical Activity (DAPA) - an exercise intervention to improve cognition in people with mild to moderate dementia: study protocol for a randomized controlled trial.
Atherton N. et al, (2016), Trials, 17
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.
Howard R. et al, (2015), Lancet Neurol, 14, 1171 - 1181
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
McCloud TL. et al, (2015), Cochrane Database Syst Rev